ophthalmic drugs market size

1
Ophthalmic Drugs Market 2020-2027
Industry Survey, Growth, Competitive
Landscapeand Forecasts to 2027
REQUEST SAMPLE
VIEW REPORTS
2
Ophthalmic Drugs Market 2020-2027

Market Highlights Owing to the rising cases of
eye diseases, the demand for an effective
treatment option has also been escalating. In the
recent years, various new and existing marketers
have come up with effective drugs. For instance,
in November 2017, Bausch Lomb, a U.S.-based
company, received the FDA approval for Vyzulta
(latanoprostene bunod ophthalmic solution). The
drug is designed for the reduction of intraocular
pressure in patients with glaucoma or ocular
hypertension. A number of factors such as rising
prevalence of eye diseases, growing awareness,
huge research funding in ophthalmology, unmet
medical needs, rising competition among market
players, improving regulatory framework, aging
population, and increasing government assistance,
are a few factors propelling the growth of the
global ophthalmic drugs market size . According
to the 2017 statistics suggested by the World
Health Organization (WHO), the chronic eye
disease is the main cause of vision loss,
globally However, the high cost associated with
a diagnosis of eye diseases, side effects of
available treatment options, and lack of
healthcare insurance may hamper the growth of the
market. According to the ophthalmic drugs market
forecast it is expected to grow at a CAGR 6.0
during the period of 2017 to 2023.
. 
3
Ophthalmic Drugs Market 2020-2027
Regional Analysis The Americas dominates the
ophthalmic drugs market owing to the presence of
patient population, rising prevalence of eye
diseases, well-developed technology, high
healthcare expenditure, and the presence of the
leading players. According to the glaucoma
research foundation, in the United States, more
than 120,000 are blind because of glaucoma. This
accounts for 9 to 12 of all the cases of
blindness. It is also reported that over 3
million Americans have glaucoma, but only a few
of them know they have it. It is also reported
that glaucoma accounts for more than 10 million
visits to physicians each year. In November 2017,
Bausch Lomb, a U.S.-based company, received the
FDA approval for Vyzulta (latanoprostene bunod
ophthalmic solution). The drug is designed for
the reduction of intraocular pressure in patients
with glaucoma or ocular hypertension. In December
2017, Rhopressa (netarsudil ophthalmic solution)
by Aerie Pharmaceuticals has also received the
FDA approval for the treatment of glaucoma or
ocular hypertension Europe holds the second
position in the ophthalmic drugs market. It is
expected that the government support towards
research and development expenditure, increasing
competition among marketers, and amendments in
reimbursement policies in healthcare are likely
to drive the European market. Asia Pacific is the
fastest growing ophthalmic drugs market owing to
a huge patient pool, increasing demand, and
development in healthcare technology.
4
Ophthalmic Drugs Market 2020-2027
Segmentation The global ophthalmic drugs market
is segmented on the basis of indication, drug
class, type of dosage, product, distribution
channel. On the basis of indication, the market
is classified as glaucoma, retinal disorders,
inflammation/infection, dry eye, allergies,
uveitis, and others. On the basis of the drug
class, the market is classified as antiallergy,
anti-VEGF agents, anti-inflammatory,
antiglaucoma, and others. The anti-inflammatory
class is further segmented into nonsteroidal
drugs and steroidal drugs. On the basis of type
of dosage, the market is classified as eye drops,
eye solutions, ointments, capsules and tablets,
and gels. On the basis of the product, the market
is classified as prescription drugs and OTC
drugs. On the basis of the distribution channel,
the market is classified as hospital pharmacies,
online pharmacies, drug stores, and
others. Request free sample _at_https//www.marketre
searchfuture.com/sample_request/5753
5
Ophthalmic Drugs Market 2020-2027
Key Players Some of the key players in the global
ophthalmic drugs market are Actavis Generics,
Allergan Plc, Bausch Lomb Inc., Genentech,
Inc., Merck Co., Inc., Pfizer Inc., Regeneron
Pharmaceuticals, Inc., Santen Pharmaceutical Co.,
Ltd., Shire Plc, Sun Pharmaceutical Industries
Limited, Teva Pharmaceutical Industries Ltd.,
Valeant Pharmaceuticals International, Inc., and
others. Get full Report and TOC
_at_https//www.marketresearchfuture.com/reports/opht
halmic-drugs-market-5753
6
ABOUT US
MARKET RESEARCH FUTURE At Market Research Future
(MRFR), we enable our customers to unravel the
complexity of various industries through our
Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports
(3R), Continuous-Feed Research (CFR), and Market
Research Consulting Services. MRFR team have
supreme objective to provide the optimum quality
market research and intelligence services to our
clients. Our market research studies by products,
services, technologies, applications, end users,
and market players for global, regional, and
country level market segments, enable our clients
to see more, know more, and do more, which help
to answer all their most important questions. In
order to stay updated with technology and work
process of the industry, MRFR often plans
conducts meet with the industry experts and
industrial visits for its research analyst
members. For more information kindly visit
www.marketresearchfuture.com or contact us at
info_at_marketresearchfuture.com Copyright 2018
Market Research Future All Rights Reserved. This
document contains highly confidential information
and is the sole property of Market Research
Future. No part of it may be circulated, copied,
quoted, or otherwise reproduced without the
written approval of Market Research Future.
7
(No Transcript)